These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23316818)

  • 1. A brief history of FDA compounding oversight.
    Shulman ST
    Pediatr Ann; 2013 Jan; 42(1):2-3. PubMed ID: 23316818
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulating compounding pharmacies after NECC.
    Outterson K
    N Engl J Med; 2012 Nov; 367(21):1969-72. PubMed ID: 23134357
    [No Abstract]   [Full Text] [Related]  

  • 3. Shattuck lecture. Innovation, regulation, and the FDA.
    Hamburg MA
    N Engl J Med; 2010 Dec; 363(23):2228-32. PubMed ID: 21121835
    [No Abstract]   [Full Text] [Related]  

  • 4. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 5. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later.
    Avorn J; Kesselheim A; Sarpatwari A
    N Engl J Med; 2018 Sep; 379(12):1097-1099. PubMed ID: 30231220
    [No Abstract]   [Full Text] [Related]  

  • 6. Learning about the safety of drugs--a half-century of evolution.
    Avorn J
    N Engl J Med; 2011 Dec; 365(23):2151-3. PubMed ID: 22150034
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA milestones.
    FDA Consum; 2006; 40(1):36-8. PubMed ID: 16528826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA regulation of tobacco.
    Nitzkin JL
    N Engl J Med; 2008 Nov; 359(19):2070; author reply 2070-1. PubMed ID: 18987378
    [No Abstract]   [Full Text] [Related]  

  • 9. The Evolution of Federal Regulation of Human Drugs in the United States: An Historical Essay.
    Hutt PB
    Am J Law Med; 2018 May; 44(2-3):403-451. PubMed ID: 30106657
    [No Abstract]   [Full Text] [Related]  

  • 10. An Interview with Robert Califf.
    Landau M
    Clin Chem; 2017 Jan; 63(1):5-13. PubMed ID: 28062605
    [No Abstract]   [Full Text] [Related]  

  • 11. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 12. The FDA clinical trial process: effectuating change in the regulatory framework governing clinical trials to account for the historical shift from "traditional" to "new" phase I trials.
    Aldes JL
    Health Matrix Clevel; 2008; 18(2):463-500. PubMed ID: 19739574
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulating Homeopathic Products - A Century of Dilute Interest.
    Podolsky SH; Kesselheim AS
    N Engl J Med; 2016 Jan; 374(3):201-3. PubMed ID: 26789866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA law enforcement: critical to product safety.
    Rados C
    FDA Consum; 2006; 40(1):21-7. PubMed ID: 16528823
    [No Abstract]   [Full Text] [Related]  

  • 15. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 16. Bodies of evidence: activists, patients, and the FDA regulation of Depo-Provera.
    Kline W
    J Womens Hist; 2010; 22(3):64-87. PubMed ID: 20857592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

  • 18. Ashes to ashes: why FDA regulation of tobacco advertising may mark the end of the road for the Marlboro man.
    Paralusz KM
    Am J Law Med; 1998; 24(1):89-122. PubMed ID: 9607105
    [No Abstract]   [Full Text] [Related]  

  • 19. Invisible monuments and the costs of pharmaceutical regulation: twenty-five years of drug lag debate.
    Daemmrich A
    Pharm Hist; 2003; 45(1):3-17. PubMed ID: 12691078
    [No Abstract]   [Full Text] [Related]  

  • 20. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.